Thus, FATP4-mediated FA activation could lead to alterations of various polar lipids and neutral lipids which in turn could play a crucial role for development of MAFLD/NAFLD in vivo. Here, SLC27A4 is linked to metabolic dysfunction-associated steatotic liver disease.